Posted by Michael Wonder on 03 Mar 2020
Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura
2 March 2020 - Cablivi is the first treatment approved in Canada for aTTP, a life-threatening blood clotting disorder.
Following a priority review, Health Canada has approved Cablivi (caplacizumab) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy.
aTTP is a rare blood disorder that causes clots to form in blood vessels throughout the body, which may lead to damage to critical organs and can cause fatal complications.
